Magdalene Moran

Magdalene Moran

Company: Carraway Therapeutics

Job title: President & Chief Scientific Officer

Seminars:

Enhancing Lysosomal Function as a Therapeutic Strategy for Parkinson’s Disease 2:00 pm

Investigating lysosomal dysfunction in neurodegenerative diseases andwhat this means from a drug development perspective Exploring activating TRPML1 as potential treatment for GBA-PD Looking through the crystal ball: Outlining future directionsRead more

Panel Discussion: Integrating Biomarkers Throughout the Trajectory of CNS Drug Discovery & Development to Guide Clinical Decisions 12:00 pm

Discussing & debating whether biopharma should strive to achieve disease modification or improvement in quality of life when developing therapies for Alzheimer’s Exploring the impact of Aducanumab on international approval for neurodegenerative disease Learning what steps you must take to tailor your drug development approach to meet regulatory standardsRead more

day: Day 2 afternoon

Enhancing Lysosomal Function as a Therapeutic Strategy for Parkinson’s Disease 11:30 am

Investigating lysosomal dysfunction in neurodegenerative diseases and what this means from a drug development perspective Exploring activating TRPML1 as potential treatment for GBA-PD Looking through the crystal ball: Outlining future Caraway directionsRead more

day: Track B - Day 2

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.